OncoSec Medical Inc (ONCSQ)

[hschlauch]

Forgot to mention, according to one of the company's presentations (I forget which one) the next product will be a P2A-linked multigene construct using low voltage.

I think it will be a combination of encoded IL-12, an adjuvant with tumor-specific antigen, an expression promotor, and a co-stimulatory molecule.

Based on existing data, the P2A link leads to statistically significant changes in protein expressions. This is quite a big deal if you're trying to elevate Interleukin 12 expression and resulting interferon gamma and PDL1 levels. Nonresponders consistently show low levels of both.

Low voltage leads to vast improvements in transfection rates.

I am basing all of this on presentations and patents filings.